Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25

Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side

Piramal Enterprises appoints Gautam Doshi as Additional Director

His experience covers a wide range of areas including advisory services in the field of accounting, taxation, corporate and commercial laws, and regulatory matters

Alembic Pharma gets USFDA approval for Glycopyrrolate Injection USP

This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.

Laurus Labs planning Rs. 2,000 Cr Capex

On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions

Healthcare firms discover ways to use VR to treat neurological diseases, says GlobalData

The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.

Novartis maintains growth momentum; Confirms FY’22 Group guidance

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.

Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%

Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business

NHA join hands with NABH to expedite implementation of ABDM

NABH shall encourage and provide assistance in onboarding their accredited/certified facilities on ABDM’s Health Facility Registry

AIIA organises multi-cultural dance competition for Ayurveda Day 2022

RPG Life Sciences Q2 FY23 revenue up 20%; PBT up 21%

In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs